Inmune Bio, Inc. 8-K Filing
Ticker: INMB · Form: 8-K · Filed: Dec 3, 2025 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | Dec 3, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $454,000, $240,000 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Inmune Bio, Inc. (ticker: INMB) to the SEC on Dec 3, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma); $454,000 (agreement, restating his base salary to $454,000 per annum and restating his option gran); $240,000 (agreement, restating his base salary to $240,000 per annum. The foregoing summaries of).
How long is this filing?
Inmune Bio, Inc.'s 8-K filing is 2 pages with approximately 607 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 607 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-12-03 16:15:27
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
- $454,000 — agreement, restating his base salary to $454,000 per annum and restating his option gran
- $240,000 — agreement, restating his base salary to $240,000 per annum. The foregoing summaries of
Filing Documents
- ea0268270-8k_inmune.htm (8-K) — 25KB
- ea026827001ex10-1_inmune.htm (EX-10.1) — 11KB
- ea026827001ex10-2_inmune.htm (EX-10.2) — 9KB
- 0001213900-25-117828.txt ( ) — 212KB
- inmb-20251202.xsd (EX-101.SCH) — 3KB
- inmb-20251202_lab.xml (EX-101.LAB) — 33KB
- inmb-20251202_pre.xml (EX-101.PRE) — 22KB
- ea0268270-8k_inmune_htm.xml (XML) — 4KB
02 Departure of Directors or Certain Officers; Election of
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 2, 2025, INmune Bio Inc. (the "Company") and David J. Moss, the Company's President and Chief Executive entered into an amendment to Mr. Moss's employment agreement, dated November 26, 2025, to correct a mistake in the original agreement, restating his base salary to $454,000 per annum and restating his option grant under the Second Amended and Restated INmune Bio Inc. 2021 Stock Incentive Plan, as amended and in effect, to 750,000 shares subject to his option. On December 2, 2025, the Company and Cory Ellspermann, the Company's Chief Financial Officer entered into an amendment to Mr. Ellspermann employment agreement, dated November 26, 2025, to correct a mistake in the original agreement, restating his base salary to $240,000 per annum. The foregoing summaries of the amendments to the employment agreements of Messrs. Moss and Ellspermann are qualified in their entirety by reference to the full text of such amendments, which are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference. 1
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Amendment to Employment Agreement, dated December 2, 2025, between INmune Bio Inc. and David Moss 10.2 Amendment to Employment Agreement, dated December 2, 2025, between INmune Bio Inc. and Cory Ellspermann 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: December 3, 2025 By: /s/ David Moss David Moss Chief Executive Officer 3